Overview of oral azole drugs as systemic antifungal therapy

Seminars in Respiratory and Critical Care Medicine

Volumn 18, Issue 3, 1997, Pages 301-309

  Hoesley, Craig ^a   Dismukes, William E ^a,b  

^a University of Alabama at Birmingham   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

Antifungal therapy; Azoles; Mycoses

Indexed keywords

4 [4 [4 [4 [[5 (2,4 DIFLUOROPHENYL)TETRAHYDRO 5 (1H 1,2,4 TRIAZOL 1 YLMETHYL)FURAN 3 YL]METHOXY]PHENYL] 1 PIPERAZINYL] PHENYL] 2,4 DIHYDRO 2 (1 ETHYL 2 HYDROXYPROPYL) 3H 1,2,4 TRIAZOLE 3 ONE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BONE MARROW TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; ENDOCRINE DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MYCOSIS; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT INDICATION;

EID: 0030809253     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1070999     Document Type: Conference Paper

References (99)

1. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72
2. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992; 14(Suppl 1).S161-9
3. Zuckerman JM, Tunkel AR. Itraconazole: a new triazole antifungal agent Infect Control Hospital Epidemiol 1994;15: 397-410
4. Borgers M. Mechanism of action of antifungal drugs with special reference to the imidazole derivative Rev Infect Dis 1980;2:520-34
5. Yoshida Y, Aoyama Y. Interaction of azole antifungal agents with cytochrome P-450 purified from Saccharomyces cerevisiae microsome. Biochem Pharmacol 1987;36:229-35
6. Sud IJ, Feingold DS. Heterogenicity of action mechanisms with antimycotic imidazoles. Antimicrob Agents Chemother 1981;20:71-4
7. Gallis HA, Drew RH, Pickard WW. Ainphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29
8. DeMuria D, Forrest A, Rich J, et al. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993;37:2187-92
9. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34
10. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole in healthy male volunteers. Antimicrob Agents Chemother 1993;37: 778-84
11. Smith D, Van de Velde V, Woestenborghs R, Gazzard BG. The pharmacokinetics of itraconazole in AIDS patients. J Pharm Pharmacol 1992;44:618-19
12. Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome. Ann Intern Med 1988;109:471-3
13. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39:877-916
14. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R. Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-13
15. Brammer KW, Farrow PR, Faulkner JK Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(Suppl 3):S318-26
16. Schafer-Korting M. Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 1993;25:329-41
17. Tucker RM, Williams PL, Arathoon EG, et al. Pharmacokinetics of oral fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 1988;32:369-73
18. Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Cauwebergh G. Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract 1990;44(Suppl 9):50-6
19. Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of [14C] fluconazole in humans. Drug Metab Dispos Biol Fate Chem 1991;19:764-7
20. Van Cauteren H, Heykants J, De Coster R, Cauwenbergh C. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987;9(Suppl 1):S104-8
21. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and hemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990;29:221-6
22. Debruyne D, Ryckelynck JP, Moulin M, Huralt de Ligny B, Levaltier B, Bigot MC. Pharmacokinetics of fluconazole in patients undergoing continuous peritoneal dialysis. Clin Pharmacokinet 1990;18:491-8
23. Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988;32:1595-7
24. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995;50:658-90
25. Dismukes WE, Cloud G, Bowles C, et al. Treatment, of blastomycosis and histoplasmosis with ketoconazole. Ann Intern Med 1985;103:861-72
26. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole: analysis of 33 cases. Gastroenterology 1984;86:503-13
27. Pont A, Graybill JR, Craven PC, et al. High dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984;144:2150-3
28. Perfect JR, Lindsay MH, Drew RH. Adverse drug reaction to systemic antifungals. Prevention and management. Drug Safety 1992;7:323-63
29. Guilame M, De Prez C, Cogan E. Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Am J Gastroenterol 1996;91:165-7
30. Pappas PG, Kaufmann CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med 195;123: 354-7
31. Mercurio MG, Elewski BE. Thrombocytopenia caused by fluconazole therapy. J Am Acad Dermatol 1995;32:525-6
32. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6
33. Lavrijsen AP, Balmus KJ, Nugteren-Huying, et al. Hepatic injury associated with itraconazole. Lancet 1992;340:251-2
34. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35: 707-13
35. Phillips P, Graybill JR, Fetchick R, Dunn JF. Adrenal response to corticotropm therapy with itraconazole. Antimicrob Agents Chemother 1987;31:647-9
36. Horst HA, Parwaresch R, Loffler H. Thrombocytopenia and leukopenia associated with itraconazole. Ann Intern Med 1996;125:156-7
37. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1984; 331:1681-3
38. Tucker RM, Denning DW, Hanson LA, et al. Interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14: 165-74
39. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P-450 enzymes. Ann Pharmacother 1995;29:619-24
40. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporine by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6
41. Baciewicz AM, Baciewicz F. Ketoconazole and fluconazole drug interactions. Arch Intern Med 1993;153:1970-6
42. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-9
43. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16:400-3
44. Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991;35:1765-71
45. Kupp CA, Brater DC, Relue J, et al. A pharmacokinetic interaction study between didanosine (DDI) and ketoconazole in HIV patients. Clin Pharmacol Ther 1992;51:155
46. Moreno F, Hardin TC, Rinaldi MG, Graybill JR. Itraconazoledidanosine excipient interaction. JAMA 1993;269:1508
47. Drayton J, Dickinson G, Rinadi MG. Co-administration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994;18:266
48. Itraconazole. Medical Letter 1993;35:7-9
49. Rowe BR, Thorpe J, Barnett A. Safety of fluconazole in women taking oral hypoglycemic agents. Lancet 1992;339: 255
50. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-18
51. Crane JK, Smith HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993;95:445-6
52. The interaction of ketoconazole, itraconazole and erythromycin with the in vitro metabolism of antihistamines in human liver microsomes. Allergy 1993;48(Suppl):34
53. Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients with human immunodeficiency virus. J Infect Dis 1994;169: 1103-7
54. Smith AG. Potentiation of oral anticoagulants by ketoconazole. Br Med J 1984;288:188
55. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. Br Med J 1990;301:669
56. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Interaction of triazolam and ketoconazole. Lancet 1995;345:191
57. Varhe A. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996;41:319-23
58. Gannon RH. Fluconazole-nortriptyline drug interaction. Ann Pharmacother 1992;26:1456
59. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995;33:134-5
60. Taylor SA, Gupta AK, Walter SE, Shear NH. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996;132:350-2
61. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6
62. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72
63. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800
64. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of oral itraconazole for invasive aspergillosis. Am J Med 1994;97:135-44
65. Dismukes WE, Bradsher Jr RW, Cloud GA, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992;93:489-97
66. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995;20:267-71
67. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients with neutropenia. N Engl J Med 1994;331:1325-30
68. Anaisse EN, Vartivarian SE, Abi-Said B, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6
69. Van't Wout JW, Novakova I, Verhagen CA, Fibbe WE, dePauw BE, van der Meer JW. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomized comparative study with amphotericin B. J Infect Dis 1991;22:45-52
70. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991;91:137-41
71. Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995;98: 259-56.
72. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. Am J Med 1990;89:282-90
73. Galgiani JW, Stevens DA, Graybill JR, Dismukes WE, Cloud GA. Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400 mg and 800 mg doses and observations at higher doses AmJ Med 1988;84:603-10
74. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993;119:28-35
75. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;36:690-2
76. De Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90
77. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole OL amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8
78. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome Am J Med 1995;98:336-42
79. Wheat J, Hafner R, Wulfson M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with AIDS. Ann Intern Med 1993;118:610-16
80. Naranno MS, Trujillo M, Munera MI, et al. Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol 1990;28:67-76
81. Negroni R, Robles AM, Arechavala A, Tuculet MA, Galimberti R Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Rev Infect Dis 1980;2: 643-9
82. Sharkey-Mathis PK, Kaufmann CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993;95:279-85
83. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7
84. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51
85. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective randomized, double-blind study. J Infect Dis 1995;171:1545-52
86. Winston DJ, Chandrasekar PII, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993;118:495-503
87. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B Ann Intern Med 1994;120:913-18
88. Thunnisen PL, Sizoo W, Hendriks WD. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991;39:84-91
89. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two non-randomized studies. Rev Infect Dis 1987;9(Suppl 1):S94-9
90. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infection in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5
91. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4
92. Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV infected patients. Lancet 1995;345:548-52
93. McKinsey D, Wheat J, Cloud G, et al. Itraconazole is effective primary prophylaxis against systemic fungal infections in patients with advanced HIV infection. Abstracts of the 36th Intcrscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, DC, American Society for Microbiology, 1996;LB9 (Abstract)
94. Perfect JR. Antifungal prophylaxis: To prevent or not. Am J Med 1993;94:233-4
95. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-4
96. Nguyen MH, Peacock Jr JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and anti-fungal resistance. Am J Med 1996;100: 617-23
97. Cameron M, Schell W, Bruch S, et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;37:2449-53
98. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus infected patients. J Infect Dis 1996;173:219-25
99. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8